Test, track, treat using wearable sensors for management of Parkinson’s disease: 12‑month prospective observational United Arab Emirates study using Parkinson’s Kinetograph (EmPark-PKG Study)

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms that necessitate ongoing clinical evaluation and medication adjustments. Home-based wearable sensor monitoring offers a detailed and continuous record of patient symptoms, potentially enh...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Neural Transmission Vol. 132; no. 4; pp. 591 - 601
Main Authors: Metta, Vinod, Qamar, Mubasher A., Poplawska-Domaszewicz, Karolina, Ibrahim, Huzaifa, Hussain, Hasna, Nalarakettil, Afsal, Tanjung, Gloria, Chaudhuri, K. Ray
Format: Journal Article
Language:English
Published: Vienna Springer Vienna 01.04.2025
Subjects:
Aged
Antiparkinson Agents - therapeutic use
Disease Progression
Female
Follow-Up Studies
Humans
Hypokinesia
Levodopa - therapeutic use
Male
Medicine
Medicine & Public Health
Middle Aged
Neurology
Neurology and Preclinical Neurological Studies - Original
Neurology and Preclinical Neurological Studies - Original Article
Neurosciences
Parkinson Disease - diagnosis
Parkinson Disease - drug therapy
Parkinson Disease - physiopathology
Prospective Studies
Psychiatry
Severity of Illness Index
United Arab Emirates
Wearable Electronic Devices
United Arab Emirates
UAE
PKG
Parkinson’s disease
Remote monitoring
Objective measurements
ISSN:0300-9564, 1435-1463, 1435-1463
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms that necessitate ongoing clinical evaluation and medication adjustments. Home-based wearable sensor monitoring offers a detailed and continuous record of patient symptoms, potentially enhancing disease management. The EmPark-PKG study aims to evaluate the effectiveness of the Parkinson’s KinetoGraph (PKG), a wearable sensor device, in monitoring and tracking the progression of motor symptoms over 12 months in Emirati and non-Emirati PD patients. Fifty PD patients (32% Emirati, 68% non-Emirati) were assessed at baseline and a 12-month follow-up. Clinical evaluations included levodopa equivalent daily dosage (LEDD) and motor and non-motor assessments. Concurrently, the PKG provided metrics such as bradykinesia score (BKS) and dyskinesia score (DKS). Statistical analyses were conducted to determine changes from baseline to six months, differences between Emirati and non-Emirati groups, and correlations between PKG metrics and clinical assessments. Significant reductions in LEDD and improvements in both motor and non-motor scores were observed from baseline to six months (p < 0.05). PKG-guided medication adjustments were associated with enhanced motor and non-motor outcomes (p < 0.05). Specifically, non-Emirati patients exhibited a significant reduction in LEDD (Z = − 2.010, p = 0.044), whereas Emirati patients did not (Z = − 0.468, p = 0.640). Both groups showed significant improvements in motor scale scores and motor complication scores. Spearman correlation analysis revealed strong relationships between PKG metrics and subjective clinical assessments (p < 0.001). The EmPark-PKG study demonstrates the potential benefits of remote PKG monitoring for personalised motor symptom management in PD. PKG supports a stepped care paradigm by enabling bespoke medication titration based on objective data, facilitating tailored and effective patient care.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0300-9564
1435-1463
1435-1463
DOI:10.1007/s00702-024-02873-0